News
Genzyme’s Most Recent News
inv_genz_news Genzyme General News
| May 7, 2008 |
Preliminary Results from Phase 2 Genzyme Study | | April 25, 2008 |
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen | | April 23, 2008 |
Genzyme Reports Strong First-Quarter Growth | | April 22, 2008 |
Genzyme to Build New R&D Center in Beijing | | April 21, 2008 |
Genzyme Provides Update on Myozyme® Manufacturing | | April 14, 2008 |
Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy | | March 19, 2008 |
Genzyme Withdraws Bioenvision’s European Filing of Evoltra® in Elderly AML Patients | | March 10, 2008 |
Genzyme Announces Presentation of New Positive Data on Carticel® | | March 6, 2008 |
Genzyme Launches Renvela® in the U.S. for Dialysis Patients | | February 13, 2008 |
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year |
Genzyme News—One Year Archive >
Genzyme Financial News >
|
|
|
|
CONTACT INFORMATION: |
|
Genzyme Investor Relations
500 Kendall Street
Cambridge, MA 02142
T: 617 252 7500
F: 617 374 7368
Patrick Flanigan – 617 768 6563
Investor Information Line
U.S. T: 800 905 4369
Outside the U.S. T: 678 999 4572
Shareholder Contact
For questions about your shares, replacement of a lost stock certificate or a change of address call our transfer agent.
American Stock Transfer
59 Maiden Lane
New York, NY 10038
T: 212 936 5100
or
Genzyme Shareholder Services
T: 617 768 6686
|
|
|
|
Home
